A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Sponsor
Sinocelltech Ltd.
Study ID
NCT07562022
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Follicular Lymphoma (FL)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • SCTB35 injection — DRUG
    SCTB35 will be subcutaneously administered at a dose as specified
  • Rituximab — DRUG
    Intravenous Infusion
  • Lenalidomide — DRUG
    Oral Capsules

Study Details

The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).

Key Dates

Start date
May 31, 2026
Status verified
Apr 2026
Primary completion
May 31, 2028
Completion
Jun 30, 2029

Study Design

Enrollment
93 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SCTB35 and Lenalidomide
  • Active Comparator: Rituximab and Lenalidomide

Primary Outcome Measure

Adverse Events [ Time Frame: Up to approximately 3 years ]

Related Studies